Abstract: Systems and methods are described for avoiding redundant data transfers using delta coding techniques when reliably and opportunistically communicating data to multiple user systems. According to embodiments, user systems track received block sequences for locally stored content blocks. An intermediate server intercepts content requests between user systems and target hosts, and deterministically chucks and fingerprints content data received in response to those requests. A fingerprint of a received content block is communicated to the requesting user system, and the user system determines based on the fingerprint whether the corresponding content block matches a content block that is already locally stored. If so, the user system returns a set of fingerprints representing a sequence of next content blocks that were previously stored after the matching content block.

Abstract: Embodiments seek to improve web page loading time using server-machine-driven hint generation for based on client-machine-driven feedback. For example, client computers having page renderers are in communication with content servers and hinting processors. The hinting processors can use hinting feedback from multiple page rendering instances to automatically generate hints for optimizing loading and/or rendering of those pages. In some implementations, in response to page requests from the page renderers, content servers can request hints from hinting processors and send those hints to the requesting page renderers for use in improving the page loading experience. In other implementations, in response to page requests from the page renderers, content servers can instruct the requesting page renderers to contact an appropriate hinting processor and to retrieve appropriate hints therefrom for use in improving the page loading experience.

Abstract: Systems and methods are described for subscriber-driven resource shifting in an attempt to maximize delivery of requested content to subscribers while minimizing the impact of satisfying those requests to network infrastructure resources. For example, when a media plan subscriber requests access to media content under the media plan, a determination is made that the media can be delivered at an earlier timeframe for a particular cost or at a later timeframe for a lower cost. Accordingly, an offer is presented to the requesting subscriber either to receive the media in the earlier timeframe at a higher cost, or to receive the media at a later timeframe in exchange for a discount (e.g., watch now for $4.99 or in 24 hours for free). Embodiments further handle delayed delivery of the content, notification of the delayed delivery to the subscriber, accounting for the delayed delivery, and/or other related functions.

Abstract: A method for treating an individual who has been identified as having Alzheimer's disease by administering orally to the individual a therapeutically effective amount of ladostigil or a pharmaceutically active salt thereof, wherein the therapeutically effective amount is 70 mg per day, 140 mg per day, or 200 mg per day. Also, a unit dosage form of ladostigil or a pharmaceutically active salt thereof in an amount of 50 mg, 70 mg, 80 mg or 100 mg.

Abstract: A vascular testing system includes a first pressure cuff assembly positionable about a limb of a patient and a controller. The first pressure cuff assembly includes a pressure bladder and a first array of acoustic sensors, the first array including a plurality of acoustic sensor elements arranged circumferentially relative to the pressure bladder. The controller is configured to concurrently sense vascular data at two or more discrete testing locations utilizing at least two different sets of the acoustic sensors of the first array each positioned at or near one of the discrete testing locations. Each set of the acoustic sensors includes one or more of the plurality of acoustic sensor elements.

Abstract: A system (10) analyzes signals representative of a subject's brain activity in a signal processor (12) for information indicating the subject's current activity state and for predicting a change in the activity state. One preferred embodiment uses a combination of nonlinear filtering methods to perform real-time analysis of the electro-encephalogram (EEG) or electro-corticogram (ECoG) signals from a subject patient for information indicative of or predictive of a seizure, and to complete the needed analysis at least before clinical seizure onset. The preferred system then performs an output task for prevention or abatement of the seizure, or for recording pertinent data.

Abstract: A method and system for use by a Customs Agency for clearing shipments of goods into a country is disclosed. A customs resource application may be used to integrate alert information, news, research, and communications capabilities. Customs inspectors may use the resource application with a conventional computer, or with a portable device in the field as they perform customs inspections. The portable device provides access to alert information regarding shipments that are to be inspected by the inspector, and provides alert resolution capabilities so that the inspector can clear shipments into the country from the location of the inspection and/or shipped goods without requiring the inspector to return to a field office to clear the goods.

Abstract: A method and system for use by a Customs Agency for clearing shipments of goods into a country is disclosed. A customs resource application may be used to integrate alert information, news, research, and communications capabilities. Customs inspectors may use the resource application with a conventional computer, or with a portable device in the field as they perform customs inspections. The portable device provides access to alert information regarding shipments that are to be inspected by the inspector, and provides alert resolution capabilities so that the inspector can clear shipments into the country from the location of the inspection and/or shipped goods without requiring the inspector to return to a field office to clear the goods.

Abstract: A method for treating an individual who has been identified as having Alzheimer's disease by administering orally to the individual a therapeutically effective amount of ladostigil or a pharmaceutically active salt thereof, wherein the therapeutically effective amount is 70 mg per day, 140 mg per day, or 200 mg per day. Also, a unit dosage form of ladostigil or a pharmaceutically active salt thereof in an amount of 50 mg, 70 mg, 80 mg or 100 mg.

Abstract: A system (10) analyzes signals representative of a subject's brain activity in a signal processor (12) for information indicating the subject's current activity state and for predicting a change in the activity state. One preferred embodiment uses a combination of nonlinear filtering methods to perform real-time analysis of the electro-encephalogram (EEG) or electro-corticogram (ECoG) signals from a subject patient for information indicative of or predictive of a seizure, and to complete the needed analysis at least before clinical seizure onset. The preferred system then performs an output task for prevention or abatement of the seizure, or for recording pertinent data.

Abstract: This invention provides compounds having the structure: wherein R1 is methyl and R2 is H, or R1 is ethyl and R2 is hydroxymethyl; R3 is H or propargyl; and R4 is either H or t-butyloxycarbonyl; or an enantiomer or a pharmaceutically acceptable salt thereof. This invention further provides the use of a therapeutically effective amount of such compounds to treat a subject afflicted with a psychiatric disorder, Parkinson's disease, Alzheimer's disease, dementia, or a neurological disorder.

Abstract: The subject invention provides a pharmaceutical composition comprising N-propargyl-1(R)-aminoindan mesylate; a pharmaceutically acceptable carrier; and greater than 0.7 ppm but less than 30 ppm in total of a compound having the structure: and any salts of the compound.

Abstract: The subject invention provides a pharmaceutical composition comprising N-propargyl-1(R)-aminoindan mesylate; a pharmaceutically acceptable carrier; and greater than 0.7 ppm but less than 30 ppm in total of a compound having the structure: and any salts of the compound.

Abstract: This invention is directed to compounds of the following formula (I): wherein R is either: wherein R1 and R2 are as defined in the specification; the use of these compounds for treating inflammatory disorders; and pharmaceutical compositions comprising a therapeutically effective amount of the above-defined compounds.

Abstract: This invention provides compounds having the structure: wherein R1 is methyl and R2 is H, or R1 is ethyl and R2 is hydroxymethyl; R3 is H or propargyl; and R4 is either H or t-butyloxycarbonyl; or an enantiomer or a pharmaceutically acceptable salt thereof. This invention further provides the use of a therapeutically effective amount of such compounds to treat a subject afflicted with a psychiatric disorder, Parkinson's disease, Alzheimer's disease, dementia, or a neurological disorder.

Abstract: The subject invention provides methods of treating a subject afflicted with Parkinson's disease, memory disorder, depression, hyperactive syndrome, Attention Deficit Disorder, dementia, brain ischemia, stroke, head trauma injury, spinal trauma injury, neurotrauma, neurodegenerative disease, neurotoxic injury, multiple sclerosis, nerve damage, affective illness, schizophrenia or symptoms of withdrawal from an addictive substance, using the mesylate salt of R(+)-N-propargyl-1-aminoindan.

Abstract: A cosmetic topical formulation and method are directed toward diminishing skin wrinkling and fine lines and improving skin tone. It contains a matrix metalloproteinase inhibitor, MMPI, e.g. batimastat or marimastat, and a natural estrogen, e.g., a true estrogen compound, such as 17-beta estradiol, or an estrogen-like steroid (such as various phytoestrogens found in herbal preparations). Exemplary phytoestrogens include triterpenoid glycosides. Certain compositions of this invention are useful for minimizing photodamage to skin, while in other embodiments, a composition according to this invention is useful to prevent or minimize the adverse effects on skin induced by cigarette smoking. The method of the invention involves administering the components such as in a dermal preparation.

Abstract: The subject invention provides methods of treating a subject afflicted with Parkinson's disease, memory disorder, depression, hyperactive syndrome, Attention Deficit Disorder, dementia, brain ischemia, stroke, head trauma injury, spinal trauma injury, neurotrauma, neurodegenerative disease, neurotoxic injury, multiple sclerosis, nerve damage, affective illness, schizophrenia or symptoms of withdrawal from an addictive substance, using the mesylate salt of R(+)-N-propargyl-1-aminoindan.

Abstract: A beam steering module comprised of a mirror stack array in close proximity to a collimator array controllably steers photons along two axis and in a direction substantially less than 90 degrees to the collimator orientation. Several configurations of the module are described using single and double axis mirror rotation and relay optics. Optical telecommunications switches are shown using modules coupled to each other along flat and curved surfaces, with and without use of fold mirror and enabling a plurality of configuration options including photodetector optical power monitoring schemes that require no external power taps.

Abstract: Disclosed are compounds having the structure: wherein Z is —OH or —O•; and A is: wherein X and Y are independently NR1 or O, where R1 is H or C1-C4 alkyl; and R2 is H, C1-C4 alkyl or t-butoxycarbonyl, wherein W is C3-C4 alkynyl; and R1 is H or C1-C4 alkyl, or wherein R1 is H, C1-C4 alkyl, or C3-C4 alkynyl; and R3 is H, OH, O(C1-C4 alkyl), or a halogen, optically active enantiomers, pharmaceutically acceptable salts of the compounds, pharmaceutical compositions containing such compounds or salts, and processes for their preparation. The subject invention also provides methods of alleviating symptoms of neurologic, autoimmune, and inflammatory disorders caused by the presence of reactive oxygen species, methods of preventing oxidation of lipids, proteins, or deoxyribonucleic acids on a cellular level, and methods of protecting human red blood cells from lysis by O2 radicals.